Home > Insider Trading > Filing (0001415889-25-008505)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1660334	Verrica Pharmaceuticals Inc.	VRCA	Pharmaceutical Preparations (2834)	463137900

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1805359	G. Christopher Hayes	C/O Verrica Pharmaceuticals Inc. 44 West Gay Street, Suite 400 West Chester PA 19380	Chief Legal Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-03-17	4,315	$0.65	176,458	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2025-03-14	250,000	$0.00	250,000	$0.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
250,000		2035-03-14	No	4	A	Direct

Footnotes

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date.